Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

Antiviral Research

Volumn 118, Issue , 2015, Pages 110-117

  Dong, Chunsheng ^a   Qu, Liang ^a   Wang, Haoyi ^b   Wei, Lin ^a   Dong, Yuansu ^a   Xiong, Sidong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

CRISPR Cas9; DNA targeting; HBV; Viral replication

Indexed keywords

ANTIVIRUS AGENT; CIRCULAR DNA; CORE PROTEIN; CRE RECOMBINASE; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; GUIDE RNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; SINGLE GUIDE RNA; UNCLASSIFIED DRUG; VIRUS DNA; DRUG CARRIER; ENDONUCLEASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; FEMALE; GENE TARGETING; HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; LIVER CELL; METABOLISM; PHYSIOLOGY; PLASMID; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS B VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRISPR-ASSOCIATED PROTEINS; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, VIRAL; DRUG CARRIERS; ENDONUCLEASES; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; MICE, INBRED BALB C; PLASMIDS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84927513847     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.03.015     Document Type: Article

References (34)

1. R. Barrangou RNA-mediated programmable DNA cleavage Nat. Biotechnol. 30 2012 836 838
2. L. Belloni, T. Pollicino, F. De Nicola, F. Guerrieri, G. Raffa, M. Fanciulli, G. Raimondo, and M. Levrero Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function Proc. Natl. Acad. Sci. USA 106 2009 19975 19979
3. Y. Bi, L. Sun, D. Gao, C. Ding, Z. Li, Y. Li, W. Cun, and Q. Li High-efficiency targeted editing of large viral genomes by RNA-guided nucleases PLoS Pathog. 10 2014 e1004090
4. K. Bloom, A. Ely, C. Mussolino, T. Cathomen, and P. Arbuthnot Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases Mol. Ther. 21 2013 1889 1897
5. J. Chen, W. Zhang, J. Lin, F. Wang, M. Wu, C. Chen, Y. Zheng, X. Peng, J. Li, and Z. Yuan An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases Mol. Ther. 22 2014 303 311
6. S.W. Cho, S. Kim, J.M. Kim, and J.S. Kim Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease Nat. Biotechnol. 31 2013 230 232
7. L. Cong, F.A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P.D. Hsu, X. Wu, W. Jiang, L.A. Marraffini, and F. Zhang Multiplex genome engineering using CRISPR/Cas systems Science 339 2013 819 823
8. T.J. Cradick, K. Keck, S. Bradshaw, A.C. Jamieson, and A.P. McCaffrey Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs Mol. Ther. 18 2010 947 954
9. M.L. Cuestas, V.L. Mathet, J.R. Oubina, and A. Sosnik Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection Pharm. Res. 27 2010 1184 1202
10. H. Ebina, N. Misawa, Y. Kanemura, and Y. Koyanagi Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus Sci. Rep. 3 2013 2510
11. D. Ganem, and R. Schneider Hepadnaviridae: the viruses and their replication D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, S.E. Straus, M.A. Martin, B. Roizman, Fields Virology fourth ed. 2001 Lippincott Williams & Wilkins Philadelphia
12. B. Gao, Z. Duan, W. Xu, and S. Xiong Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain Hepatology 50 2009 424 433
13. E.M. Kennedy, L.C. Bassit, H. Mueller, A.V. Kornepati, H.P. Bogerd, T. Nie, P. Chatterjee, H. Javanbakht, R.F. Schinazi, and B.R. Cullen Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease Virology 476 2015 196 205
14. A. Kramvis, M. Kew, and G. Francois Hepatitis B virus genotypes Vaccine 23 2005 2409 2423
15. C.L. Lai, C.K. Ching, A.K. Tung, E. Li, J. Young, A. Hill, B.C. Wong, J. Dent, and P.C. Wu Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial Hepatology 25 1997 241 244
16. M. Levrero, T. Pollicino, J. Petersen, L. Belloni, G. Raimondo, and M. Dandri Control of cccDNA function in hepatitis B virus infection J. Hepatol. 51 2009 581 592
17. H. Li, V. Haurigot, Y. Doyon, T. Li, S.Y. Wong, A.S. Bhagwat, N. Malani, X.M. Anguela, R. Sharma, L. Ivanciu, S.L. Murphy, J.D. Finn, F.R. Khazi, S. Zhou, D.E. Paschon, E.J. Rebar, F.D. Bushman, P.D. Gregory, M.C. Holmes, and K.A. High In vivo genome editing restores haemostasis in a mouse model of haemophilia Nature 475 2011 217 221
18. S.R. Lin, H.C. Yang, Y.T. Kuo, C.J. Liu, T.Y. Yang, K.C. Sung, Y.Y. Lin, H.Y. Wang, C.C. Wang, Y.C. Shen, F.Y. Wu, J.H. Kao, D.S. Chen, and P.J. Chen The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo Mol. Ther. Nucleic Acids 3 2014 e186
19. L. Lisowski, A.P. Dane, K. Chu, Y. Zhang, S.C. Cunningham, E.M. Wilson, S. Nygaard, M. Grompe, I.E. Alexander, and M.A. Kay Selection and evaluation of clinically relevant AAV variants in a xenograft liver model Nature 506 2014 382 386
20. J. Lucifora, S. Arzberger, D. Durantel, L. Belloni, M. Strubin, M. Levrero, F. Zoulim, O. Hantz, and U. Protzer Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection J. Hepatol. 55 2011 996 1003
21. J.C. Miller, M.C. Holmes, J. Wang, D.Y. Guschin, Y.L. Lee, I. Rupniewski, C.M. Beausejour, A.J. Waite, N.S. Wang, K.A. Kim, P.D. Gregory, C.O. Pabo, and E.J. Rebar An improved zinc-finger nuclease architecture for highly specific genome editing Nat. Biotechnol. 25 2007 778 785
22. J.C. Miller, S. Tan, G. Qiao, K.A. Barlow, J. Wang, D.F. Xia, X. Meng, D.E. Paschon, E. Leung, S.J. Hinkley, G.P. Dulay, K.L. Hua, I. Ankoudinova, G.J. Cost, F.D. Urnov, H.S. Zhang, M.C. Holmes, L. Zhang, P.D. Gregory, and E.J. Rebar A TALE nuclease architecture for efficient genome editing Nat. Biotechnol. 29 2011 143 148
23. T. Mino, T. Mori, Y. Aoyama, and T. Sera Gene- and protein-delivered zinc finger-staphylococcal nuclease hybrid for inhibition of DNA replication of human papillomavirus PLoS One 8 2013 e56633
24. G. Moraleda, J. Saputelli, C.E. Aldrich, D. Averett, L. Condreay, and W.S. Mason Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus J. Virol. 71 1997 9392 9399
25. A. Plymoth, S. Viviani, and P. Hainaut Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention Cancer Lett. 286 2009 15 21
26. Z. Qi, G. Li, H. Hu, C. Yang, X. Zhang, Q. Leng, Y. Xie, D. Yu, Y. Gao, K. Lan, and Q. Deng Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice J. Virol. 88 2014 8045 8056
27. J.T. Schiffer, M. Aubert, N.D. Weber, E. Mintzer, D. Stone, and K.R. Jerome Targeted DNA mutagenesis for the cure of chronic viral infections J. Virol. 86 2012 8920 8936
28. M.L. Schilsky Hepatitis B "360" Transplant. Proc. 45 2013 982 985
29. C. Seeger, and J.A. Sohn Targeting hepatitis B virus with CRISPR/Cas9 Mol. Ther. Nucleic Acids 3 2014 e216
30. M.A. Sells, A.Z. Zelent, M. Shvartsman, and G. Acs Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions J. Virol. 62 1988 2836 2844
31. H. Wang, H. Yang, C.S. Shivalila, M.M. Dawlaty, A.W. Cheng, F. Zhang, and R. Jaenisch One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering Cell 153 2013 910 918
32. C.I. Wooddell, D.B. Rozema, M. Hossbach, M. John, H.L. Hamilton, Q. Chu, J.O. Hegge, J.J. Klein, D.H. Wakefield, C.E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H.P. Vornlocher, A. McLachlan, and D.L. Lewis Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol. Ther. 21 2013 973 985
33. S. Zhen, L. Hua, Y.H. Liu, L.C. Gao, J. Fu, D.Y. Wan, L.H. Dong, H.F. Song, and X. Gao Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus Gene Ther. 2015
34. Y. Zhu, T. Yamamoto, J. Cullen, J. Saputelli, C.E. Aldrich, D.S. Miller, S. Litwin, P.A. Furman, A.R. Jilbert, and W.S. Mason Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis J. Virol. 75 2001 311 322